Morphosys AG To Discuss Results From The Primary Analysis Of The Ongoing Single-Arm Phase 2 Clinical Trial L-MIND Conference Call Transcript
Ladies and gentlemen, welcome to the MorphoSys conference call. (Operator Instructions) The conference is being recorded. (Operator Instructions) Now I would like to turn the call over to Sarah Fakih. Please go ahead.
Good afternoon, good morning, and welcome to our Q&A call following the publications of the primary L-MIND analysis data on Thursday last week.
My name is Sarah Fakih and I'm the Head of Corporate Communications and Investor Relations at MorphoSys. With me on the call today are Simon Moroney, our Chief Executive Officer; Jens Holstein, our Chief Financial Officer; and Malte Peters, our Chief Development Officer.
Before we start, I would like to remind you that during this conference call, we will discuss certain forward-looking statements concerning the development of MorphoSys core technologies, the progress of its current research and development programs and the initiation of additional programs. Should actual results differ from the company's
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
